Display options
Cite
Donnelly ED, Rakhra S, Helenowski I, et al. Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma. J Contemp Brachytherapy. 2012;4(3):135-40doi: 10.5114/jcb.2012.30679.
Donnelly, E. D., Rakhra, S., Helenowski, I., Gopalkrishnan, M., Lurain, J., Schink, J., Singh, D., Strauss, J., & Small, W. (2012). Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma. Journal of contemporary brachytherapy, 4(3), 135-40. https://doi.org/10.5114/jcb.2012.30679
Donnelly, Eric D, et al. "Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma." Journal of contemporary brachytherapy vol. 4,3 (2012): 135-40. doi: https://doi.org/10.5114/jcb.2012.30679
Donnelly ED, Rakhra S, Helenowski I, Gopalkrishnan M, Lurain J, Schink J, Singh D, Strauss J, Small W. Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma. J Contemp Brachytherapy. 2012 Sep;4(3):135-40. doi: 10.5114/jcb.2012.30679. Epub 2012 Sep 29. PMID: 23346142; PMCID: PMC3551376.
Copy Download .nbib Format: NLM
Share it on

J Contemp Brachytherapy. 2012 Sep;4(3):135-40. doi: 10.5114/jcb.2012.30679. Epub 2012 Sep 29.

Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma.

Journal of contemporary brachytherapy

Eric D Donnelly, Sunpreet Rakhra, Irene Helenowski, Mahesh Gopalkrishnan, John Lurain, Julian Schink, Diljeet Singh, Jonathan Strauss, William Small

Affiliations

  1. Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

PMID: 23346142 PMCID: PMC3551376 DOI: 10.5114/jcb.2012.30679

Abstract

PURPOSE: The optimal dosimetric parameters and planning techniques for high-dose-rate vaginal brachytherapy (HDR-VB) are unclear. Our aim was to evaluate the utility of bladder and rectal dosimetry for patients receiving HDR-VB for postoperative treatment of endometrial carcinoma.

MATERIAL AND METHODS: Patients with endometrial cancer who underwent postoperative HDR-VB from January 1, 2004 through December 31, 2010 were included. All patients underwent primary surgery consisting of total hysterectomy and bilateral salpingo-oophrectomy (TH-BSO) with or without lymph node dissection and were treated with HDR-VB without pelvic external beam radiotherapy (EBRT) or chemotherapy. Demographic, pathologic, dosimetric and clinical data were collected.

RESULTS: One hundred patients were identified with the majority of patients receiving HDR-VB in 700 cGy × 3 fractions (45%) or 550 cGy x 4 fractions (53%). No plan was altered based on bladder dosimetry at the time of planning. The rate of acute urinary reactions (< 90 days from beginning of RT) grades 1 and 2 were 14% and 2%, respectively. The rate of late urinary reactions (> 90 days after RT) grades 1 and 2 were 7% and 3%, respectively. Dose to the bladder point did not correlate with urinary toxicity. No rectal toxicity was reported by patients receiving HDR-VB.

CONCLUSIONS: In the setting of HDR-VB without EBRT, the measured dose to the bladder point does not predict urinary toxicity and is very unlikely to indicate the need to change the treatment plan. The treatment of endometrial carcinoma utilizing HDR-VB alone is associated with very low rates of high-grade acute or late bladder toxicity.

Keywords: brachytherapy; endometrial cancer; high-dose-rate

References

  1. CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36 - PubMed
  2. Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):413-8 - PubMed
  3. Radiother Oncol. 1992 Jul;24(3):137-46 - PubMed
  4. Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1033-9 - PubMed
  5. Brachytherapy. 2011 Jul-Aug;10(4):313-7 - PubMed
  6. Lancet. 2000 Apr 22;355(9213):1404-11 - PubMed
  7. Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):111-7 - PubMed
  8. Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):417-25 - PubMed
  9. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1502-7 - PubMed
  10. Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):507-13 - PubMed
  11. Brachytherapy. 2012 Jan-Feb;11(1):58-67 - PubMed
  12. Lancet. 2010 Mar 6;375(9717):816-23 - PubMed
  13. Brachytherapy. 2007 Jul-Sep;6(3):201-6 - PubMed
  14. Gynecol Oncol. 2004 Mar;92(3):744-51 - PubMed

Publication Types

Grant support